Weak pipeline? Why, Sanofi ex­ecs are sud­den­ly over the moon about their prospects

It’s amaz­ing what a vague top-line re­port on a Phase II study plus a rel­a­tive­ly small bolt-on deal can do to a Big Phar­ma’s fu­ture prospects.

I’d say just ask new Sanofi CEO Paul Hud­son, but you don’t have to. He’ll read­i­ly vol­un­teer his grow­ing en­thu­si­asm now that he’s had a chance to set­tle in­to his lead­er­ship role. And you haven’t even been giv­en a glimpse of what’s around the cor­ner.

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN